Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Off-Label Opioid Promotion: US FDA ‘Does Not Object’ To Intranasal Deterrence Data, Egalet Says

Executive Summary

In decision that reflects policy confluence of opioid abuse deterrence, off-label communications and marketing exclusivity, FDA will allow Egalet to distribute truthful, nonmisleading information about Arymo ER's intranasal abuse-deterrence data even though the long-acting opioid was blocked from receiving a labeling claim.

Advertisement

Related Content

Opioids: Intellipharmaceutics' Pursuit Of IV-Only Deterrence Claim May Backfire
Abuse-Deterrent Opioids: Rexista To Test New FDA Leadership's Approach
Drug Promotion: Exclusivity Warrants Narrow Exception From Free Speech Protections
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
Abuse-Deterrent Opioids: US FDA Follows The ‘Route Of Abuse’ To Exclusivity
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
Off-Label Communication: When Does It Align With Approved Labeling?
Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
FDA Panel Nod For Egalet Opioid's Deterrence Claims Made Easier By Tablet Hardness
Off-Label Preclearance Process Eyed As Potential Fix For FDA's Policy Dilemma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120347

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel